Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering on possible TRA partners

Executive Summary

Talks with pharmaceutical companies about a potential collaboration on its Phase III thrombin receptor antagonist for atherothrombosis have reached a stumbling block because potential partners have no comparably valuable asset to offer in return, CEO Fred Hassan said during the Morgan Stanley CEOs Unplugged conference Jan. 3. The firm is apparently looking for a quid pro quo relationship: "We are asking them to show us a quid that has the same kind of value so that we can diversify on both sides, and unfortunately for the larger companies they have nothing to show us. That is the biggest challenge," he said. Schering has "talked to practically all the big companies" and remains open to further discussions, he added. Schering announced its interest in partnering on TRA several months ago 1("The Pink Sheet" Oct. 29, 2007, p. 5)...

You may also be interested in...



Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel